AAPL275.15-18.02 (-6.15%) ▼|ABBV243.14+8.25 (+3.51%) ▲|ABT93.24+2.75 (+3.04%) ▲|ACN125.82-3.33 (-2.58%) ▼|ADBE193.41-3.14 (-1.60%) ▼|AMAT668.00+79.04 (+13.42%) ▲|AMD532.57+13.52 (+2.60%) ▲|AMGN352.82+1.43 (+0.41%) ▲|AMT168.72-5.74 (-3.29%) ▼|AMZN227.01-7.36 (-3.14%) ▼|AVGO378.91-3.17 (-0.83%) ▼|AXP342.46-0.10 (-0.03%) ▼|BA218.12-2.13 (-0.97%) ▼|BAC58.19+0.46 (+0.80%) ▲|BKNG177.05-4.23 (-2.33%) ▼|BLK971.92-10.68 (-1.09%) ▼|BMY55.39+0.39 (+0.71%) ▲|BNY145.43+1.87 (+1.30%) ▲|BRK-B487.81-7.00 (-1.41%) ▼|C144.98+1.39 (+0.97%) ▲|CAT1,057.01+62.56 (+6.29%) ▲|CL91.06-0.82 (-0.89%) ▼|CMCSA22.69+0.05 (+0.22%) ▲|COF204.90+4.42 (+2.20%) ▲|COP106.41-0.51 (-0.48%) ▼|COST942.24-18.73 (-1.95%) ▼|CRM150.19-2.57 (-1.68%) ▼|CSCO118.97-0.77 (-0.64%) ▼|CVS104.66+2.79 (+2.74%) ▲|CVX172.24+0.79 (+0.46%) ▲|DE630.76+30.01 (+5.00%) ▲|DHR193.21+4.34 (+2.30%) ▲|DIS98.05-3.07 (-3.04%) ▼|DUK127.11+0.58 (+0.46%) ▲|EMR145.34+3.90 (+2.76%) ▲|FDX329.44+12.61 (+3.98%) ▲|GD344.70+0.38 (+0.11%) ▲|GE371.36+5.48 (+1.50%) ▲|GEV1,085.47+27.82 (+2.63%) ▲|GILD123.84-1.31 (-1.05%) ▼|GM78.53-0.42 (-0.53%) ▼|GOOG342.19-2.84 (-0.82%) ▼|GOOGL343.71-1.57 (-0.45%) ▼|GS1,065.09-11.82 (-1.10%) ▼|HD345.00+2.14 (+0.62%) ▲|HON231.24+3.82 (+1.68%) ▲|IBM258.27-4.69 (-1.78%) ▼|INTC132.87+0.96 (+0.73%) ▲|INTU255.07-7.26 (-2.77%) ▼|ISRG399.69-2.14 (-0.53%) ▼|JNJ244.88+3.88 (+1.61%) ▲|JPM335.12+1.67 (+0.50%) ▲|KO80.42-0.18 (-0.22%) ▼|LIN522.28+6.55 (+1.27%) ▲|LLY1,127.69+10.43 (+0.93%) ▲|LMT505.02+13.38 (+2.72%) ▲|LOW221.93+0.48 (+0.22%) ▲|LRCX401.82+27.00 (+7.20%) ▲|MA488.92-5.49 (-1.11%) ▼|MCD264.54-9.34 (-3.41%) ▼|MDLZ61.20-0.54 (-0.87%) ▼|MDT80.52+0.39 (+0.49%) ▲|META542.87-14.93 (-2.68%) ▼|MMM167.97+2.06 (+1.24%) ▲|MO73.21+1.14 (+1.58%) ▲|MRK125.45+4.85 (+4.02%) ▲|MS221.04+1.18 (+0.54%) ▲|MSFT352.83-12.62 (-3.45%) ▼|MU1,213.56+165.64 (+15.81%) ▲|NEE87.70+0.08 (+0.09%) ▲|NFLX70.90-0.95 (-1.32%) ▼|NKE40.90-0.92 (-2.20%) ▼|NOW89.52-4.28 (-4.56%) ▼|NVDA195.74-3.17 (-1.59%) ▼|ORCL152.46-5.07 (-3.22%) ▼|PEP139.52-2.75 (-1.93%) ▼|PFE23.67-0.37 (-1.54%) ▼|PG148.50-3.54 (-2.33%) ▼|PLTR107.27-6.24 (-5.50%) ▼|PM178.93+1.62 (+0.91%) ▲|QCOM204.90+7.58 (+3.84%) ▲|RTX186.59+1.53 (+0.83%) ▲|SBUX103.16-0.36 (-0.35%) ▼|SCHW89.44-1.95 (-2.13%) ▼|SO95.91+0.13 (+0.14%) ▲|SPG225.49+3.34 (+1.50%) ▲|T22.42+0.05 (+0.22%) ▲|TMO505.75+13.55 (+2.75%) ▲|TMUS181.57+0.78 (+0.43%) ▲|TSLA375.12-0.35 (-0.09%) ▼|TXN311.81+8.70 (+2.87%) ▲|UBER72.25-1.60 (-2.17%) ▼|UNH415.53+9.73 (+2.40%) ▲|UNP267.73+7.77 (+2.99%) ▲|UPS109.31+3.17 (+2.99%) ▲|USB61.21+1.10 (+1.83%) ▲|V330.52-1.71 (-0.51%) ▼|VZ46.07+0.39 (+0.85%) ▲|WFC84.74+0.44 (+0.52%) ▲|WMT115.78-3.23 (-2.71%) ▼|XOM137.55+0.65 (+0.47%) ▲|AAPL275.15-18.02 (-6.15%) ▼|ABBV243.14+8.25 (+3.51%) ▲|ABT93.24+2.75 (+3.04%) ▲|ACN125.82-3.33 (-2.58%) ▼|ADBE193.41-3.14 (-1.60%) ▼|AMAT668.00+79.04 (+13.42%) ▲|AMD532.57+13.52 (+2.60%) ▲|AMGN352.82+1.43 (+0.41%) ▲|AMT168.72-5.74 (-3.29%) ▼|AMZN227.01-7.36 (-3.14%) ▼|AVGO378.91-3.17 (-0.83%) ▼|AXP342.46-0.10 (-0.03%) ▼|BA218.12-2.13 (-0.97%) ▼|BAC58.19+0.46 (+0.80%) ▲|BKNG177.05-4.23 (-2.33%) ▼|BLK971.92-10.68 (-1.09%) ▼|BMY55.39+0.39 (+0.71%) ▲|BNY145.43+1.87 (+1.30%) ▲|BRK-B487.81-7.00 (-1.41%) ▼|C144.98+1.39 (+0.97%) ▲|CAT1,057.01+62.56 (+6.29%) ▲|CL91.06-0.82 (-0.89%) ▼|CMCSA22.69+0.05 (+0.22%) ▲|COF204.90+4.42 (+2.20%) ▲|COP106.41-0.51 (-0.48%) ▼|COST942.24-18.73 (-1.95%) ▼|CRM150.19-2.57 (-1.68%) ▼|CSCO118.97-0.77 (-0.64%) ▼|CVS104.66+2.79 (+2.74%) ▲|CVX172.24+0.79 (+0.46%) ▲|DE630.76+30.01 (+5.00%) ▲|DHR193.21+4.34 (+2.30%) ▲|DIS98.05-3.07 (-3.04%) ▼|DUK127.11+0.58 (+0.46%) ▲|EMR145.34+3.90 (+2.76%) ▲|FDX329.44+12.61 (+3.98%) ▲|GD344.70+0.38 (+0.11%) ▲|GE371.36+5.48 (+1.50%) ▲|GEV1,085.47+27.82 (+2.63%) ▲|GILD123.84-1.31 (-1.05%) ▼|GM78.53-0.42 (-0.53%) ▼|GOOG342.19-2.84 (-0.82%) ▼|GOOGL343.71-1.57 (-0.45%) ▼|GS1,065.09-11.82 (-1.10%) ▼|HD345.00+2.14 (+0.62%) ▲|HON231.24+3.82 (+1.68%) ▲|IBM258.27-4.69 (-1.78%) ▼|INTC132.87+0.96 (+0.73%) ▲|INTU255.07-7.26 (-2.77%) ▼|ISRG399.69-2.14 (-0.53%) ▼|JNJ244.88+3.88 (+1.61%) ▲|JPM335.12+1.67 (+0.50%) ▲|KO80.42-0.18 (-0.22%) ▼|LIN522.28+6.55 (+1.27%) ▲|LLY1,127.69+10.43 (+0.93%) ▲|LMT505.02+13.38 (+2.72%) ▲|LOW221.93+0.48 (+0.22%) ▲|LRCX401.82+27.00 (+7.20%) ▲|MA488.92-5.49 (-1.11%) ▼|MCD264.54-9.34 (-3.41%) ▼|MDLZ61.20-0.54 (-0.87%) ▼|MDT80.52+0.39 (+0.49%) ▲|META542.87-14.93 (-2.68%) ▼|MMM167.97+2.06 (+1.24%) ▲|MO73.21+1.14 (+1.58%) ▲|MRK125.45+4.85 (+4.02%) ▲|MS221.04+1.18 (+0.54%) ▲|MSFT352.83-12.62 (-3.45%) ▼|MU1,213.56+165.64 (+15.81%) ▲|NEE87.70+0.08 (+0.09%) ▲|NFLX70.90-0.95 (-1.32%) ▼|NKE40.90-0.92 (-2.20%) ▼|NOW89.52-4.28 (-4.56%) ▼|NVDA195.74-3.17 (-1.59%) ▼|ORCL152.46-5.07 (-3.22%) ▼|PEP139.52-2.75 (-1.93%) ▼|PFE23.67-0.37 (-1.54%) ▼|PG148.50-3.54 (-2.33%) ▼|PLTR107.27-6.24 (-5.50%) ▼|PM178.93+1.62 (+0.91%) ▲|QCOM204.90+7.58 (+3.84%) ▲|RTX186.59+1.53 (+0.83%) ▲|SBUX103.16-0.36 (-0.35%) ▼|SCHW89.44-1.95 (-2.13%) ▼|SO95.91+0.13 (+0.14%) ▲|SPG225.49+3.34 (+1.50%) ▲|T22.42+0.05 (+0.22%) ▲|TMO505.75+13.55 (+2.75%) ▲|TMUS181.57+0.78 (+0.43%) ▲|TSLA375.12-0.35 (-0.09%) ▼|TXN311.81+8.70 (+2.87%) ▲|UBER72.25-1.60 (-2.17%) ▼|UNH415.53+9.73 (+2.40%) ▲|UNP267.73+7.77 (+2.99%) ▲|UPS109.31+3.17 (+2.99%) ▲|USB61.21+1.10 (+1.83%) ▲|V330.52-1.71 (-0.51%) ▼|VZ46.07+0.39 (+0.85%) ▲|WFC84.74+0.44 (+0.52%) ▲|WMT115.78-3.23 (-2.71%) ▼|XOM137.55+0.65 (+0.47%) ▲|
21.7 C
New York
Friday, June 26, 2026

Tag: medicine

newssourceFORcompanyinformationcontent1marketreleases

Pendopharm® and KalVista® Partner to Bring First Oral On-Demand HAE Treatment to Canada

MONTREAL, June 26, 2025 /CNW/ - Pendopharm®, a division of Pharmascience Inc., has entered into an exclusive distribution agreement with KalVista Pharmaceuticals, Inc. (NASDAQ:...

Anti-CCR8 Antibodies Market to Witness Remarkable Growth Trajectory During the Forecast Period (2025-2040) Across 7MM | DelveInsight

The anti-CCR8 antibodies market holds potential in addressing unmet needs across inflammatory and cancerous diseases. The anti-CCR8 inhibitor market is expected to witness substantial...

Anti-CCR8 Antibodies Market to Witness Remarkable Growth Trajectory During the Forecast Period (2025-2040) Across 7MM | DelveInsight

The anti-CCR8 antibodies market holds potential in addressing unmet needs across inflammatory and cancerous diseases. The anti-CCR8 inhibitor market is expected to witness substantial...

Tariff Uncertainty Disrupts Healthcare Operations: New Diagnostic Survey Highlights Staffing Changes, Delayed Purchases, and Supply Chain Strain

ARLINGTON, Va., June 26, 2025 /PRNewswire/ -- A new survey of 195 diagnostic imaging and clinical lab professionals reveals that tariff policy uncertainty is...

EVA Pharma and BioPharma Town – Qiantang District, Hangzhou Sign a Strategic Cooperation Agreement

EVA Pharma Deepens Its Roots in China’s Thriving Biopharmaceutical Ecosystem with The Inauguration of Its Hangzhou Office 
EVA Pharma Deepens Its Roots in China’s Thriving Biopharmaceutical Ecosystem with The Inauguration of Its Hangzhou Office

Dr. Irfan Atcha and New Teeth Chicago™ Join The Alston as Founding Members, Welcoming the Private Club to River North

Dr. Irfan Atcha, nationally renowned dental implant surgeon and founder of New Teeth Chicago™, has officially joined The Alston, Chicago's exclusive new private member...

Everest Medicines to Host Virtual Nephrology-Focused KOL Event on June 30, 2025

SHANGHAI, June 26, 2025 (GLOBE NEWSWIRE) -- Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it will host a virtual nephrology-focused key opinion leader (KOL) event on Monday, June 30, 2025 at 8:00 AM ET. For English speakers, please click here to register. For individuals preferring instant Chinese translation, please click here.

Albany ENT & Allergy Services’ CT Manager Elected President of National Accreditation Body

ALBANY, N.Y., June 26, 2025 /PRNewswire/ -- Albany ENT & Allergy Services (AENT), the Capital Region's leading private otolaryngology practice, proudly congratulates Diane Deyoe, RT,...

BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET

PALO ALTO, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an investor webinar on Friday, July 11, 2025 at 8:00 am ET with Matthew Wicklund, M.D., FAAN, Professor of Neurology and Vice Chair for Research, Department of Neurology at the University of Texas (UT) Health Science Center San Antonio.

Cellarity Initiates Phase 1 Clinical Study of CLY-124, a First-in-Class Globin-Switching Oral Medicine for the Treatment of Sickle Cell Disease

Initiation follows successful IND clearance based on preclinical data package indicating robust increase in fetal hemoglobin with no cytotoxicity Novel Globin-Switching mechanism derived from...

Herbalgy Celebrates 25th Anniversary with “Goal-Getter Giveaway” Campaign

Join Us to Watch Arsenal Take on Tottenham# Download high-resolution images: HONG KONG, June 26, 2025 /PRNewswire/ -- Herbalgy proudly presents The Herbalgy Trophy –...

CARsgen Therapeutics Announces NDA Acceptance of Satri-cel by China’s NMPA

SHANGHAI, June 25, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that...

Electronic Health Records (EHR) Market Valued at USD 33.45 Billion in 2024, Set to Grow at 4.59% CAGR Through 2032 | AnalystView Market Insights

EHR industry is booming due to rising digitalization, regulatory mandates, and demand for streamlined patient data access. Key players like Epic Systems, Cerner (Oracle), and Allscripts dominate with innovative, cloud-based solutions. Growing investments in telehealth and AI integration continue to accelerate market expansion across hospitals and ambulatory care settings. 
EHR industry is booming due to rising digitalization, regulatory mandates, and demand for streamlined patient data access. Key players like Epic Systems, Cerner (Oracle), and Allscripts dominate with innovative, cloud-based solutions. Growing investments in telehealth and AI integration continue to accelerate market expansion across hospitals and ambulatory care settings.

Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26

Company to host Investor Webcast on Thursday, June 26, 2025, at 8:30 am E.T. 
Company to host Investor Webcast on Thursday, June 26, 2025, at 8:30 am E.T.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsMedicine

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers